

## Chairman Speech

### CHAIRMAN'S SPEECH

Good Afternoon Ladies and Gentlemen,

I extend a warm welcome to all of you at this Twenty Nineth (29<sup>th</sup>) Annual General Meeting of your Company through Video Conferencing/ Other Audio Visual Means

The financial year 2021-22 began on a subdued note owing to repeated attacks of the pandemic, taking a severe toll on lives and economies. As the world navigated through the pandemic, the escalation of geopolitical strife compounded the crisis and brought numerous other challenges in the form of strained geopolitical and trade relations, a runaway inflation and unprecedented volatility in commodity costs. In the face of such flux, the Kimia showed resilience and adaptability, ensuring continuous supply of medicines to help patients gain access to their medication.

### Expansion of R & D

Your Company has evolved much stronger and larger with increased infrastructure during the year 2021-22 and has forged ahead in development of innovative technologies, cost improvement in existing products & indigenous development of key raw materials.

The R & D strength has increased significantly to more than 60 scientists and has commercialized more than 25 products while 9-10 molecules are under development and will be very soon on developed stage.

### API Growth

I wish you to inform that API market is predicted to grow at CAGR of around 6.30% during 2022-23. The API market was estimated to worth around USD 189.51 Billion in 2021 and is expected to reach USD 308.96 Billion by 2028.

#### KIMIA BIOSCIENCES LIMITED

Regd. Office/Works  
Village Bhondsi, Damdama Lake Road,  
Gurugram, Haryana-122102  
Tel.: +91 9654746544, 9654206544



compliance.kimia@gmail.com | info@kimiabiosciences.com | www.kimiabiosciences.com | CIN No.: L24239HR1993PLC032120

Your Company has globally made a remarkable foothold in the API market in this year. The Export earnings of the Company has exponentially increased by 30% during the year.

Your Company has great business affiliations with top pharmaceuticals companies of India.

### **Awards & Facilitations**

Your Company has been selected amongst the top 10 Pharmaceutical API manufacturer for the year 2022 by India Pharma Outlook.

I am happy to inform that with the support and hard work of our Team, Employees and workers, I have been awarded among the 10 Best CEO in 2022 by Trade flog, I have been also awarded among the 10 Best Corporate Leaders in Delhi in the year 2021 and 2022 in recognition of the fervent leadership and mentoring delivered for the development of the corporate sector in Delhi and the inspiring leadership stories by CEO Insights.

I am happy to share that, because of your believe and faith in me, I have been selected among top 10 CEO from Pharma and Life Sciences in the year 2022 by CEO Insights.

### **Events**

Your Company had participated in Pharmaconex 2022 expo that was held in Cario, Egypt in the month of September 2022 and I have represented your Company along with the marketing Team.

I am happy to share that your Company has received a tremendous response in the Pharmaconex 2022 expo held in Egypt and has also decided to open a new office in Egypt.

Your Company is also participating in the Convention of Pharmaceutical Ingredients (CPHI) Frankfurt, Germany which is to be held in November 2022 and CPHI, Delhi, which is taking place at the end of November 2022.



*[Handwritten signature]*



## Financial Performance

We wish to inform you that the Financial Year 2021-22 was tough year, the challenges also offer us an opportunity to improve our processes and hence emerge as stronger Company. The Company has a vision to achieve the sales target of Rs 250 crores in the upcoming financial year.

As also specifically mentioned in the Notice of the AGM, it is informed that in Compliance with the relevant circulars, the Notice setting out the business to be transacted at the Annual General Meeting together with the Annual Report of the Company for the year 2021-22, were sent only electronically to those members whose email address is registered with the Company/ Depository Participant(s).

We look forward to perform better and generate larger revenues for your company in coming Financial Years considering these major events.

I would like to take this opportunity and thank our employees for their consistent effort to deliver the best results despite the challenges. I also take this opportunity to thank all my colleagues on the Board for their continued support and guidance. I also thank all our shareholders for their continued trust on the entire Kimia Biosciences team. At Kimia we remain committed to becoming one of the most sustainable organizations in the pharmaceutical industry. We are diligently working towards the goals set for reducing carbon emissions, replacing traditional fuel sources with renewable energy, mindful management of water and waste and conservation of biodiversity.

Our focus will remain on Continuous process innovation and Green chemistry implementation to further establish Kimia as a strong sustainable organization and deliver value added performance. I thank all the stakeholders for reposing their trust



*[Handwritten signature]*

in us. We will continue to strive for leadership through chemistry and be the most reliable supplier of high-quality API's while creating value for all our stake holders.

We see a large canvas of opportunities in front of us and we are fully prepared to leverage them with the cooperation of our people, partners and associates. I would like to take this opportunity to thank all of them, as also the Board of Directors for their invaluable guidance through this journey.



**SAMEER GOEL**

**CHAIRMAN OF THE MEETING**